Please assess the completion status of the following clinical trial:

Trial Title: Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with moderate to severe RA for whom the physician had decided to treat with golimumab according to the local product label, with the first dose being administered between 12 and 26 weeks prior to study enrollment~* Participants who have achieved an adequate therapeutic response to regular doses of golimumab, within 12 to 26 weeks of treatment~* Participants should be evaluated for tuberculosis (TB) exposure/risk factors or managed for active and latent TB (per local requirements and according to the local product label)~* Participants who have been evaluated for active/latent hepatitis B virus (HBV) and hepatitis C virus (HCV)~* Participants for whom, since golimumab initiation, a complete medical record is available~Exclusion criteria:~* Participants who have received and terminated golimumab treatment in the past~* Participants that have been treated with golimumab for more than 26 weeks prior to enrolment in the study~* Participants with use of any other investigational agent less than or equal to 30 days before starting treatment with golimumab~* Participants with suspected latent TB, having not received prophylactic treatment of at least 4 weeks~* Participants with suspected or active TB~* Participants with active/latent HBV or HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Golimumab (Type: None): Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).